Kala Pharmaceuticals (KALA) PT Raised to $17 at H.C. Wainwright Following NDA Review Approval by FDA
Tweet Send to a Friend
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Kala Pharmaceuticals (NASDAQ: KALA) to $17.00 (from $14.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
